<DOC>
	<DOCNO>NCT00407472</DOCNO>
	<brief_summary>This study Phase I , open label , randomize , 2-period , 2-sequence , crossover study design assess relative bioavailability Saizen administer ATS-1 needle-free injection device standard needle syringe . Informed consent obtain prior screen . All screen assessment establish subject eligibility perform 21 day dose . Randomization Pre-dose Day 1 , subject randomize one two treatment sequence : Sequence 1 : SC Saizen administer Standard needle syringe ( Period 1 ) follow administration use ATS-1 device ( Period 2 ) . Sequence 2 : SC Saizen administer ATS-1 device ( Period 1 ) follow administration use standard needle syringe ( Period 2 ) . Subjects resident Unit approximately 19:00 Day -1 Day 2 ( approximately 30 hour ( h ) post dose ) treatment period . An IV Stilamin infusion commence 1 h . Saizen administration stop immediately last pharmacokinetic ( PK ) blood sample take , i.e . 25 h infusion . Stilamin administer constant IV infusion rate approximately 118 mg/h ( 40 mL/h ) , correspond 1.65 mg/kg body weight/h person weigh 70kg . Dosing Saizen occur approximately 0800 0900 h Day 1 treatment period overnight fast least 10h . Subjects dose Saizen time Day 1 Periods 1 2 . There minimum 7-day washout treatment period 1 2 . Laboratory safety test , ECGs take protocol specify time point blood sample assessment glucose growth hormone take immediately predose 1 , 2 , 3 , 4 4.5 , 5 , 5.5 , 6 , 7 , 8 , 12 , 18 24 h post dose . A post-study visit take place 33+/- 3 day dose treatment period 2 .</brief_summary>
	<brief_title>ATS-1 Needle Free Injection Device Study-a Device Administering r-hGH ( Saizen ) Treat Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<criteria>Male Subjects age 21 50 Have give write informed consent Have body weight great 60 kg body mass index ( BMI ) range 22 30 ( BMI weight ( kg ) / height ( ) 2 ) Have vital sign follow normal range : Oral body temperature : 35.0 37.5 0C Blood Pressure ( BP ) : Supine BP least 3 minute supine rest Systolic BP : 90 150 mm Hg , diastolic P : 50 95 mm Hg , Supine heart rate least 3 minute rest : 40 90 bpm Be nonsmoker smoke less equal five cigarette ( use equivalent amount tobacco per day willing smoke whilst resident clinical unit Be able communicate well Principal Investigator willing comply requirement entire study Agree use barrier contraception ( condom spermicide ) study three month follow completion post study visit . Existence surgical medical condition opinion Principal Investigator might interfere absorption , distribution , metabolism elimination investigational medicinal product aim study Have clinically significant abnormality result screen safety laboratory test Have clinically significant abnormality 12lead rest ECG screen Have positive result virology examination Hepatitis surface antigen ( HBsAg ) ( due vaccination ) , Hepatitis C Virus ( HCV ) Human Immunodeficiency Virus ( HIV 1 2 ) screen History presence hypertension significant cardiovascular abnormality History presence cholelithiasis Significant history clinical evidence autoimmune , gastrointestinal , hematological , haemaoppoietic , hepatic , neurological , pancreatic renal disease History presence diabetes Definite suspect personal history family history adverse drug reaction hypersensitivity drug similar chemical structure somatotropin somtostatin Use chronic medication Presence history serious allergy ( require hospitalization prolong systemic treatment ) History presence drug alcohol abuse . The limit alcohol consumption inclusion study define average daily intake 3 unit maximum weekly intake grater 21 unit ( 1 unit equal 340 mL beer , 115 mL wine 43 mL spirit ) Loss donation 400 mL blood 12 week dose Subjects use prescription drug within 2 week overthecounter medication ( exception paracetamol multivitamin ) within 1 week dosing without prior approval investigator Administration investigational drug 12 week dose</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Bio-equivalence study healthy volunteer , indication</keyword>
	<keyword>product growth hormone deficiency</keyword>
</DOC>